Skip to page content

partitionbio

Click to slide down

Home » Grow » Sector Growth » Ambitious Essex Tech 50 » PartitionBio

About the Company: Founded in 2021, PartitionBio is a biomedical technology company based in Saffron Walden. The company focuses on developing biomolecular tools for therapeutic and synthetic biology applications, leveraging its proprietary technology platform.

Services and Products: PartitionBio specializes in exploiting liquid-liquid phase separation (LLPS) of biomolecules to develop innovative solutions for various biomedical challenges. Their technology is used to create tools for therapeutic applications, particularly for diseases associated with biomolecular condensates, such as neurodegenerative diseases, cancers, and viral infections. The company also develops synthetic biology tools that enhance enzyme kinetics and DNA amplification processes

Mission and Values: PartitionBio’s mission is to harness the power of LLPS to develop groundbreaking therapeutic solutions and synthetic biology tools. The company values innovation, scientific excellence, and collaboration, aiming to advance the understanding and application of biomolecular condensates in health and disease.

Key Strengths:

  • Innovation: PartitionBio is at the forefront of utilizing LLPS technology to create novel biomedical tools and therapies.
  • Expertise: The team comprises experts in protein engineering, condensate biology, medicinal chemistry, and high-throughput microscopy screening.
  • Research Focus: The company is dedicated to advancing scientific knowledge and developing practical applications for biomolecular condensates.
  • Collaborative Approach: PartitionBio works closely with academic and industry partners to drive innovation and achieve impactful results.

PartitionBio continues to lead the way in biomedical innovation, offering cutting-edge solutions that address some of the most pressing challenges in healthcare and synthetic biology.

Visit PartitionBio